Taysha Gene Therapies (TSHA) Cash from Investing Activities (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Cash from Investing Activities of -$3.0 million for Q1 2026, down 715.09% on a YoY basis from $491631.9 in Q1 2025, and down 1124.29% sequentially from -$247000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Cash from Investing Activities data on file, last reported at -$3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 715.09% year-over-year to -$3.0 million; the trailing twelve-month figure through Mar 2026 stood at -$3.3 million (down 448.32% YoY), and the FY2025 full-year result was -$604000.0, down 66.39% from the prior year.
- Cash from Investing Activities fell to -$3.0 million in Q1 2026, from -$247000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $62000.0 in Q2 2025 to a low of -$11.4 million in Q1 2022.
- A 5-year average of -$2.1 million and a median of -$247000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities tumbled 2039.89% in 2022 and soared 230.0% in 2024, its largest moves.
- Tracing TSHA's Cash from Investing Activities over 5 years: stood at -$2.4 million in 2022, then soared by 99.58% to -$10000.0 in 2023, then soared by 230.0% to $13000.0 in 2024, then slumped by 2000.0% to -$247000.0 in 2025, then plunged by 1124.29% to -$3.0 million in 2026.
- Business Quant data shows TSHA's Cash from Investing Activities at -$3.0 million in Q1 2026, -$247000.0 in Q4 2025, and -$48000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Taysha Gene Therapies | 2.09 Bn | 2.09 Bn | - | -3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.02 Mn |
| Mar 31, 2026 | -3.02 Mn |
| Dec 31, 2025 | -247,000.00 |
| Dec 31, 2025 | -247,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Sep 30, 2025 | -48,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | -371,000.00 |
| Mar 31, 2025 | -371,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | -35,000.00 |
| Sep 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Mar 31, 2024 | -140,000.00 |
| Dec 31, 2023 | -10,000.00 |
| Dec 31, 2023 | -10,000.00 |